Study S002306

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04572165
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 194928
Start: 2021-01-26
Primary completion: 2025-11-25
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Ozempic®; DRUG:Active Comparator; DRUG:Rybelsus®
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1214-6228; REGISTRY:EUPAS37258

Registered primary outcomes

Occurrence of first time malignant neoplasm of pancreas [From when semaglutide entered the market in Denmark, Sweden, and Norway (Q3/Q4 2018) until December 31, 2023]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.